Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
2 reports, 1 independent
Updated Oct 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nektar Therapeutics
American healthcare company
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners cut its shares rating for Akebia Therapeutics on November 3, 2026.
- Leerink Partners began coverage on Novogen Limited shares on October 20, 2026.
- Nektar Therapeutics' board granted stock options to new employees on October 23, 2026.
- Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.